Sp1295

WHAT’S NEXT IN EOE: TAKING A DEEP DIVE INTO A NEW THERAPEUTIC OPTION

Date
May 20, 2024

Presenter


Tracks

Related Products

Thumbnail for EFFICACY AND SAFETY OF THE SELECTIVE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD, IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS OVER 52 WEEKS IN THE PHASE 2 VOYAGE STUDY
EFFICACY AND SAFETY OF THE SELECTIVE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD, IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS OVER 52 WEEKS IN THE PHASE 2 VOYAGE STUDY
BACKGROUND: Etrasimod is an investigational, oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator in development to treat immune-mediated inflammatory disorders…
Thumbnail for EOSINOPHILIC ESOPHAGITIS: DISCOVER A TREATMENT OPTION FOR YOUR PATIENTS
EOSINOPHILIC ESOPHAGITIS: DISCOVER A TREATMENT OPTION FOR YOUR PATIENTS
Take an afternoon break with us to learn about a treatment option for your appropriate patient with eosinophilic esophagitis…